Comparer des méthodes

	Échelle d'évaluation fonctionnelle révisée pour la SLA (ALSFRS-R)	Échelle de Rankin modifiée (mRS)
Domaine	Neurologie	Neurologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1999	1988
Auteur d'origine	James M. Cedarbaum, NIH/NINDS	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.
Type	Clinician-rated and patient-reported hybrid	Clinician-rated ordinal scale
Source fondatrice	Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.
Alias	ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised	mRS, Rankin Scale, Modified Rankin
Apparentées	4	4
Résumé	The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.